OSCR
Oscar Health, Inc.
OSCR has the edge over XNCR overall, supported by stronger fundamentals and stronger modeled upside.
XNCR
Xencor, Inc.
XNCR has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
XNCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Strong |
XNCR's revenue and balance sheet are currently strong, but its profitability and cash flow are weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
XNCR PE Valuation
XNCR has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
XNCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect XNCR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over XNCR on earnings quality, reporting a profit while its opponent remains loss making.
XNCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.59 | +$0.13 |
| Q2 2026 | -$2.17 | +$0.19 |
| Q1 2026 | -$2.29 | +$0.75 |
| Q4 2025 | -$1.24 | +$2.34 |
| Q3 2025 | -$1.72 | +$1.70 |
| Q2 2025 | -$2.36 | +$0.74 |
| Q1 2025 | -$3.04 | -$0.66 |
| Q4 2024 | -$3.58 | -$1.38 |
XNCR is still losing money, but far less than before: $1.59 per share over the past year, against $3.58 at its worst in late 2024.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over XNCR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
XNCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $116.5M | +455% |
| Q2 2026 | $51.2M | +17% |
| Q1 2026 | $4.5M | -86% |
| Q4 2025 | $28.2M | -47% |
| Q3 2025 | $21M | +18% |
| Q2 2025 | $43.6M | +82% |
| Q1 2025 | $32.7M | +105% |
| Q4 2024 | $52.8M | +3.6% |
XNCR's revenue is recovering but still below its 2021 peak: $117M last quarter, up 455% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +246 points |
| Q2 2026 | -72% | +3.7 points |
| Q1 2026 | -1724% | -1592 points |
| Q4 2025 | -190% | -165 points |
| Q3 2025 | -226% | +84 points |
| Q2 2025 | -76% | +156 points |
| Q1 2025 | -132% | +210 points |
| Q4 2024 | -25% | +29 points |
XNCR has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over XNCR on cash generation, producing positive trailing cash flow while its opponent burns cash.
XNCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $838K | +$31.8M |
| Q2 2026 | -$56.2M | -$19.4M |
| Q1 2026 | -$68.2M | -$50.6M |
| Q4 2025 | -$52.9M | -$1.4M |
| Q3 2025 | -$31M | -$1.6M |
| Q2 2025 | -$36.8M | +$33.6M |
| Q1 2025 | -$17.7M | +$39.3M |
| Q4 2024 | -$51.5M | -400% |
XNCR has burned cash in most quarters: −$176M over the past year, against −$137M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
XNCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +2.5M shares |
| 1 year | +5.3% | +3.9M shares |
| 3 years | +29% | +17.7M shares |
| 5 years | +34% | +20M shares |
| Available history | +34% | +19.9M shares |
XNCR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
XNCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -0.9x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -0.8x | Net Cash |
| Q4 2021 | -2.8x | Net Cash |
| Q4 2019 | -2.8x | Net Cash |
XNCR has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
XNCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 81.4 | Overbought |
| Stochastic | 85.8 | Overbought |
XNCR's weekly RSI is 81 (overbought) and its Stochastic is 86 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XNCR PE vs Healthcare Sector
| Metric | XNCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XNCR has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
XNCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.1 | 36% above |
| 20 week MA | $24.3 | 57% above |
| 50 week MA | $17.5 | 118% above |
| 100 week MA | $15.0 | 154% above |
| 200 week MA | $19.0 | 101% above |
XNCR has climbed back above all five of its weekly moving averages, and it's now 101% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR's yearly returns have swung widely, from +314% in 2023 to −74% in 2021. It's up 114% so far in 2026.
XNCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $46.1 | +30% |
| 2021 | $46.1 | $40.7 | -12% |
| 2022 | $40.7 | $26.1 | -36% |
| 2023 | $26.1 | $21.2 | -19% |
| 2024 | $21.2 | $24.3 | +14% |
| 2025 | $24.3 | $15.2 | -37% |
| 2026 YTD | $15.2 | $38.1 | +151% |
XNCR has the edge over OSCR on returns for 2026, with the stronger performance.